Conference Coverage

Critical illness-related corticosteroid insufficiency guidelines explained


 

EXPERT ANALYSIS FROM THE CCC47

– When corticosteroids are used for septic shock, the dose should be low to moderate, the timing should be early, and the duration should be at least 3 days, said a speaker at the Critical Care Congress sponsored by the Society for Critical Care.

Dosing, timing, and duration are “three critical questions” critical care specialists face that are answered by the new critical illness–related corticosteroid insufficiency (CIRCI) guidelines, continued Stephen M. Pastores, MD, a cochair of the task force that developed guidelines for the diagnosis and management of CIRCI in critically ill patients.

Andrew D. Bowser/Frontline Medical News

Dr. Stephen M. Pastores

The recently published guidelines come in two parts. The first takes into account the most current evidence on the use of corticosteroids in disorders that most clinicians associate with CIRCI, including sepsis/septic shock, acute respiratory distress syndrome, and major trauma (Crit Care Med. 2017 Dec;45[12]:2078-88). Part two of the guidelines, published separately, covers other syndromes, such as influenza, meningitis, burns, and other conditions that at least 80% of the task force members agreed were associated with CIRCI (Crit Care Med. 2018 Jan;46[1]:146-148).

During his presentation, Dr. Pastores limited his remarks to discussion of sepsis and septic shock with corticosteroids. He cautioned that, despite careful deliberations by the panel, the level of evidence behind some of the recommendations was “low to moderate and never high” and that not all task force members agreed with all recommendations.

Pages

Recommended Reading

Wait at least 2 days to replace central venous catheters in patients with candidemia
MDedge Infectious Disease
In-hospital outcomes are better for vaccinated H1N1 patients
MDedge Infectious Disease
VIDEO: Rapid influenza test obviates empiric antivirals
MDedge Infectious Disease
Inpatient antiviral treatment reduces ICU admissions among influenza patients
MDedge Infectious Disease
REPROVE: Ceftazidime-avibactam noninferior to meropenem for nosocomial pneumonia
MDedge Infectious Disease
Combo therapy does not improve outcomes for A. Baumannii
MDedge Infectious Disease
Increasing sepsis survivorship creates new challenges
MDedge Infectious Disease
Hydrocortisone-fludrocortisone cuts deaths in septic shock
MDedge Infectious Disease
Preparing to respond to workplace violence
MDedge Infectious Disease
Prehospital antibiotics improved some aspects of sepsis care
MDedge Infectious Disease